|Mr. Geert R. Kersten Esq.||Chief Exec., Financial & Accounting Officer and Director||613.41k||N/A||58|
|Ms. Patricia B. Prichep||Sr. VP of Operations & Corp. Sec.||254.84k||N/A||66|
|Dr. Eyal Talor Ph.D.||Chief Scientific Officer||309.63k||N/A||61|
|Dr. Daniel H. Zimmerman Ph.D.||Sr. VP of Research - Cellular Immunology||234.44k||N/A||76|
|Mr. John Cipriano||Sr. VP of Regulatory Affairs||211.44k||N/A||75|
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The companys Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
CEL-SCI Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.